Cell-free DNA from nail clippings as source of normal control for genomic studies in hematologic malignancies

Comprehensive genomic sequencing is becoming a critical component in the assessment of hematologic malignancies, with broad implications for patients’ management. In this context, unequivocally discriminating somatic from germline events is challenging but greatly facilitated by matched analysis of...

Full description

Saved in:
Bibliographic Details
Published inHaematologica (Roma) Vol. 109; no. 10; pp. 3269 - 3281
Main Authors Krystel-Whittemore, Melissa, Petrova-Drus, Kseniya, Ptashkin, Ryan N., Ewalt, Mark D., Yao, JinJuan, Liu, Ying, Zhu, Menglei, Benhamida, Jamal, Durham, Benjamin, Kumar, Jyoti, Nafa, Khedoudja, Kiecka, Iwona, Bowman, Anita S., Gedvilaite, Erika, Casanova, Jacklyn, Lin, Yun-Te, Mohanty, Abhinita S., Rana, Satshil, Rema, Anoop Balakrishnan, Rijo, Ivelise, Chaves, Nelio, Salazar, Paulo, Yun, Anita, Lachhander, Sean, Wang, Wei, Haque, Mohammad S., Xiao, Wenbin, Roshal, Mikhail, Giralt, Sergio, Salles, Gilles, Rampal, Raajit, Stein, Eytan M., Perales, Miguel-Angel, Horwitz, Steven, Jakubowski, Ann, Ponce, Doris, Markova, Alina, Birsoy, Ozge, Mandelker, Diana, Mantha, Simon, Dogan, Ahmet, Benayed, Ryma, Ladanyi, Marc, Berger, Michael F., Brannon, A. Rose, Zehir, Ahmet, Vanderbilt, Chad, Arcila, Maria E.
Format Journal Article
LanguageEnglish
Published Italy Fondazione Ferrata Storti 01.10.2024
Ferrata Storti Foundation
Subjects
Online AccessGet full text
ISSN0390-6078
1592-8721
1592-8721
DOI10.3324/haematol.2024.285054

Cover

More Information
Summary:Comprehensive genomic sequencing is becoming a critical component in the assessment of hematologic malignancies, with broad implications for patients’ management. In this context, unequivocally discriminating somatic from germline events is challenging but greatly facilitated by matched analysis of tumor:normal pairs of samples. In contrast to solid tumors, in hematologic malignancies conventional sources of normal control material (peripheral blood, buccal swabs, saliva) could be highly involved by the neoplastic process, rendering them unsuitable. In this work we describe our real-world experience using cell-free DNA (cfDNA) isolated from nail clippings as an alternate source of normal control material, through the dedicated review of 2,610 tumor:nail pairs comprehensively sequenced by MSK-IMPACT-heme. Overall, we found that nail cfDNA is a robust germline control for paired genomic studies. In a subset of patients, nail DNA may be contaminated by tumor DNA, reflecting unique attributes of the hematologic disease and transplant history. Contamination is generally low level, but significantly more common among patients with myeloid neoplasms (20.5%; 304/1,482) than among those with lymphoid diseases (5.4%; 61/1,128) and particularly enriched in myeloproliferative neoplasms with marked myelofibrosis. When identified in patients with lymphoid and plasma-cell neoplasms, mutations commonly reflected a myeloid profile and correlated with a concurrent/evolving clonal myeloid neoplasm. Donor DNA was identified in 22% (11/50) of nails collected after allogeneic stem-cell transplantation. In this cohort, an association with a recent history of graft-versus-host disease was identified. These findings should be considered as a potential limitation to the use of nails as a source of normal control DNA but could also provide important diagnostic information regarding the disease process.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
MK-W has been an advisory board member and speaker for AstraZeneca and has provided professional services for Foundation Medicine. KPD has received an honorarium (not related to this study) from Invivoscribe, Inc. RNP is an employee of C2i Genomics. RR has received consulting fees from Incyte Corporation, Celgene/BMS, Blueprint, AbbVie, CTI, Stemline, Galecto, Pharmaessentia, Constellation/Morphosys, Sierra Oncology/GSK, Cogent, Sumitomo Dainippon, Kartos, Servier, Zentalis, and Karyopharm and has received research funding from Constellation Pharmaceuticals, Ryvu, Zentalis, and Stemline Therapeutics. MAP reports honoraria from Adicet, Allogene, Allovir, Caribou Biosciences, Celgene, Bristol-Myers Squibb, Equilium, Exevir, ImmPACT Bio, Incyte, Karyopharm, Kite/Gilead, Merck, Miltenyi Biotec, MorphoSys, Nektar Therapeutics, Novartis, Omeros, OrcaBio, Sanofi, Syncopation, VectivBio AG, and Vor Biopharma; he serves on Data Safety Monitoring Boards for Cidara Therapeutics, Medigene, and Sellas Life Sciences, and on a scientific advisory board of NexImmune; he has ownership interests in NexImmune, Omeros, and OrcaBio; and has received institutional research support for clinical trials from Allogene, Incyte, Kite/Gilead, Miltenyi Biotec, Nektar Therapeutics, and Novartis. SH is a consultant for Affimed, Abcuro Inc, Corvus, Daiichi Sankyo, Kyowa Hakko Kirin, ONO Pharmaceuticals, SeaGen, SecuraBio, Takeda, and Yingli; and has received research support from ADC Therapeutics, Affimed, C4, Celgene, Crispr Therapeutics, Daiichi Sankyo, Dren Kyowa Hakko Kirin, Millennium/Takeda, Seattle Genetics, and SecuraBio. DP has received honoraria from Incyte and Sanofi; has served on advisory boards for Evive Biotechnology (Shanghai) Ltd (formerly Generon [Shanghai] Corporation Ltd), Kadmon-Sanofi Corporation, Ceramedix, and Incyte; and has received research funding from Incyte Corporation and Sanofi. AM has received research funding from AstraZeneca, Incyte Corporation, Kintara Therapeutics, and Amryt Pharma; has provided consultancy services for ADC Therapeutics, Alira Health, AstraZeneca, Protagonist Therapeutics, OnQuality, and Janssen; and has received royalties from UpToDate. SM is the principal owner of Daboia Consulting LLC. AD receives research support from Roche and Takeda. MFB has provided consultancy services for Eli Lilly, AstraZeneca, and Paige.AI; has received research support from Boundless Bio; and has intellectual property rights with SOPHiA Genetics. CV holds equity and intellectual property rights with, and provides professional services and activities for Paige.AI. MEA has acted as a speaker for Biocartis, Invivoscribe, Physician Educational Resources (PER), Peerview Institute for Medical Education, Clinical Care Options, and RMEI Medical Education; and has acted as a consultant for Janssen Global Services, Bristol-Myers Squibb, AstraZeneca, Roche, Biocartis, and Sanofi.
Disclosures
ISSN:0390-6078
1592-8721
1592-8721
DOI:10.3324/haematol.2024.285054